2. Oral riluzole versus placebo (Russman 2003).
Riluzole | Placebo | |
Number of participants randomised | 7 | 3 |
Number (%) of participants evaluable for analysis | 7 (100%) | 3 (100%) |
Number of participants (%) who died during the 12‐month study | 4 (57%) | 3 (100%) |
Median age at death (months)* | 17 | 8 |
Range of ages at death (months)* | 5‐25 | 6‐13 |
Adverse events | 0 | 0 |
*Among the children who died during the 12‐month study. Three of the seven children treated with riluzole were alive at 30, 48 and 64 months' follow‐up.